Silo Pharma’s SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent

The new patent claims cover Silo Pharma, Inc.’s portfolio drug SPU-21, a peptide-guided anti-arthritis drug, as a method of selectively targeting inflamed synovial tissue.